Skip to main content

ORIGINAL RESEARCH article

Front. Bioeng. Biotechnol.
Sec. Synthetic Biology
Volume 12 - 2024 | doi: 10.3389/fbioe.2024.1497138
This article is part of the Research Topic Engineering actinomycetes to produce bioactive agents View all 3 articles

Discovery of thiazostatin D/E using UPLC-HR-MS2 based metabolomics and σ factor engineering of Actinoplanes sp. SE50/110

Provisionally accepted
  • 1 Microbial Genomics and Biotechnology, Center for Biotechnology, Bielefeld University, Bielefeld, Germany
  • 2 Department of Pharmacy, Faculty of Medicine and Health Sciences, UiT-The Arctic University of Norway, Tromsø, Norway
  • 3 Marbio, Faculty for Fisheries, Biosciences and Economy, UiT-The Arctic University of Norway, Tromsø, Troms, Norway
  • 4 Technology Platform Genomics, Center for Biotechnology, Bielefeld University, Bielefeld, Germany

The final, formatted version of the article will be published soon.

    As the natural producer of acarbose, Actinoplanes sp. SE50/110 has high industrial relevance. Like most actinobacteria, the strain carries several more putative biosynthetic gene clusters (BGCs) to produce further natural products, which are to be discovered. Applying a metabolomics-guided approach, we tentatively identified five further compounds that are produced by the strain: watasemycin, thiazostatin, isopyochelin, pulicatin, and aerugine. Comparison of the genomic context allowed the identification of the putative BGC, which is highly similar to the watasemycin biosynthetic gene cluster of Streptomyces venezuelae. In addition to the identified molecules, a thiazostatin-like compound was found. Isolation and following structure elucidation with 1D, 2D NMR, and HRMS was applied. The fraction containing m/z 369.0929 [M+H] + comprised in fact two highly similar compounds identified as thiazostatin D and thiazostatin E. The compounds possessed the same phenole-thiazole-thiazole molecular scaffold as the previously reported thiazostatin and watasemycin and has anti-proliferative activity against breast adenocarcinoma cell line MCF7 and human melanoma cell line A2058 while no activity again non-malignant immortalized fibroblast cell line MRC-5 was observed. We could further show that manipulation of global transcriptional regulators, with sigH (ACSP50_0507) and anti-anti-σ factor coding ACSP50_0284 as example, enabled the production manipulation of the 2-hydroxyphenylthiazoline family molecules. While manipulation of sigH enabled the shift of peak intensities between the five products of this pathway, ACSP50_0284 manipulation prevented their production. The production of a highly polar compound with m/z 462.1643 [M+H] + and calculated elemental composition C19H27NO12 was activated under the ACSP50_0284 expression and is exclusively produced by the engineered strain.

    Keywords: Actinobacteria, Actinoplanes sp. SE50/110, Natural Products, secondary metabolites, Sigma Factor, hydroxyphenylthiazoline, Metabolomics (LC-MS)

    Received: 16 Sep 2024; Accepted: 04 Nov 2024.

    Copyright: © 2024 Schlüter, Hanssen, Isaksson, Andersen, Hansen, Kalinowski and Schneider. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Yannik Karl-Heinz Schneider, Marbio, Faculty for Fisheries, Biosciences and Economy, UiT-The Arctic University of Norway, Tromsø, Troms, Norway

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.